Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Parkinson disease  (3)
  • insulin  (2)
  • Gel retardation  (1)
  • 1
    Electronic Resource
    Electronic Resource
    DNA binding activity of NtrC from Rhizobium grown on different nitrogen sources
    Amsterdam : Elsevier
    FEBS Letters 354 (1994), S. 89-92 
    Details
    ISSN: 0014-5793
    Keywords: Gel retardation ; Nitrogen regulation ; Two-component system
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Physics
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/0014-5793(94)01094-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents (1990)
    Springer
    Diabetologia 33 (1990), S. 688-695 
    Details
    ISSN: 1432-0428
    Keywords: insulin ; sulfonylurea ; combined therapy ; insulin action ; insulin secretion ; metabolic control
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Metabolic control, insulin secretion and insulin action were evaluated in seven Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral antidiabetic agents before and after two months of combined therapy with supper-time insulin (Ultratard: 0.4 U/kg body weight/day) plus premeal glibenclamide (15 mg/day). Metabolic control was assessed by 24 h plasma glucose, NEFA, and substrate (lactate, alanine, glycerol, ketone bodies) profile. Insulin secretion was evaluated by glucagon stimulation of C-peptide secretion, hyperglycaemic clamp (+7 mmol/l) and 24 h free-insulin and C-peptide profiles. The repeat studies, after two months of combined therapy, were performed at least 72 h after supper-time insulin withdrawal. Combining insulin and sulfonylurea agents resulted in a reduction in fasting plasma glucose (12.9±7 vs 10.4±1.2 mmol/l; p〈0.05) and hepaic glucose production (13.9±1.1 vs 11.1±1.1 μmol·kgc-min−1; p〈0.05). Mean 24 h plasma glucose was also lower (13.7±1.2 vs 11.1±1.4 mmol/l; p〈0.05). Decrements in fasting plasma glucose and mean 24 h profile were correlated (r=0.90; p〈0.01). HbA1c also improved (11.8±0.8 vs 8.9±0.5%; p〈0.05). Twenty-four hour profile for NEFA, glycerol, and ketone bodies was lower after teatment, while no difference occurred in the blood lactate and alanine profile. Insulin secretion in response to glucagon (C-peptide =+0.53±0.07 vs +0.43±0.07 pmol/ml) and hyperglycaemia (freeinsulin = 13.1±2.0 vs 12.3±2.2 mU/l) did not change. On the contrary, mean 24 h plasma freeinsulin (13.2±2.6 vs 17.5±2.2 mU/l; p〈0.01) and C-peptide (0.76±0.10 vs 0.98±0.13 pmol/l; p〈0.02) as well as the area under the curve (19.1±4.1 vs 23.6±3.1 U/24 h;p〈0.01 and 1.16±0.14 vs 1.38±0.18 μmol/24 h; p〈0.02 respectively) were significantly increased. The ratio between glucose infusion (M) and plasma insulin concentration (I) during the hyperglycaemic clamp studies (M/I, an index of insulin sensitivity), was not statistically different (1.40±0.25 vs 1.81±0.40 μmol·kg−1· min−1/mU·l−1). These data suggest that, in Type 2 diabetic patients with secondary failure to oral antidiabetic agents, the combination of supper-time longacting insulin and premeal sulfonylurea agents can improve metabolic control. This positive effect is possibly mediated through an increased secretion of insulin in response to physiologic stimuli.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00400571
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Insulin regulation of glucose and lipid metabolism in massive obesity (1990)
    Springer
    Diabetologia 33 (1990), S. 228-236 
    Details
    ISSN: 1432-0428
    Keywords: Obesity ; insulin ; glucose ; non-esterified fatty acids ; glucose turnover ; non-esterified fatty acid turnovers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Eight obese patients and 12 normal individuals underwent a euglycaemic insulin clamp (20 and 40 mU · m2−1 · min−1) along with continuous infusion of 3-3H-glucose and 1-14C-palmitate and indirect calorimetry. Basal plasma glucose concentration (4.7±0.3 vs 4.4±0.2 mmol/l) was similar in the two groups, whereas hepatic glucose production was slightly higher in obese individuals (1.11±0.06 vs 0.84±0.05 mmol/min) in spite of higher plasma insulin levels (17±2 vs 6±1 mU/l; p〈0.01). Insulin inhibition of hepatic glucose production was impaired in obese subjects. Glucose disposal by lean body mass was markedly reduced both at baseline (11.7±1.1 vs 15.6±0.6 μmol · kg−1 · min−1; p〈0.05) and during clamp (15.0±1.1 vs 34.4±2.8 and 26.7±3.9 vs 62.2±2.8 μmol · kg−1 · min−1; p〈0.01) Oxidative (12.2±1.1 vs 17.8±1 and 16.1±1.1 vs 51.1±1.7 μmol · kg−1 · min−1; p〈0.05−0.002) and non-oxidative glucose metabolism (3.9±1.1 vs 15.0±2.8 and 12.8±3.3 vs 38.3±2.2 μmol · kg−1 · min−1; p〈0.01−0.001) were impaired. Basal plasma concentrations of non-esterified fatty acids (635±75 vs 510±71 μmol/l) and blood glycerol (129±17 vs 56±5 μmol/l; p〈0.01) were increased in obese patients. Following hyperinsulinaemia, plasma non-esterified fatty acids (244±79 vs 69±16 and 140±2 vs 36±10 μmol/l; p〈0.01) and blood glycerol levels (79±20 vs 34±6 and 73±22 vs 29±5 μmol/l; p〈0.01) remained higher in obese subjects. Baseline non-esterified fatty acid production rate per kg of fat body mass was significantly larger in normal weight subjects (37.7±6.7 vs 14.0±1.8 μmol/l; p〈0.01) and insulin inhibition was reduced in obese patients (−41±9 vs −74±3 and −53±11 vs −82±3%; p〈0.05). Basal plasma non-esterified fatty acid utilization by lean body mass was similar in the two groups (9.8±0.9 vs 8.8±2.0 μmol · kg−1 · min−1), whereas during clamp it remained higher in obese patients (6.0±1.2 vs 2.8±2.5 and 4.9±1.3 vs 1.5±0.6 μmol · kg−1 · min−1; p〈0.1−0.05). Lipid oxidation was higher in obese individuals in spite of hyperinsulinaemia (3.7±0.3 vs 2.4±0.4 and 2.3±0.4 vs 0.9±0.3 μmol · kg−1 · min−1; p〈0.05− 0.02). An inverse correlation was found between lipid oxidation and glucose oxidation (r=0.82 and 0.93; p〈0.001) and glucose utilization (r=0.54 and 0.83; p〈0.05−0.001) both in obese and control subjects. A correlation between lipid oxidation and non-oxidative glucose metabolism was present only in normal weight individuals (r=0.75; p〈0.01). We conclude that in obesity all tissues (muscles, liver, and adipose tissue) are resistant to insulin action. Insulin resistance involves glucose as well as lipid metabolism.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00404801
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Depression in Parkinson disease: a disabling but neglected factor (1984)
    Springer
    Neurological sciences 5 (1984), S. 417-422 
    Details
    ISSN: 1590-3478
    Keywords: Parkinson disease ; depression ; disability ; diagnosis ; treatment
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Sommario A 20 parkinsoniani depressi ed a 20 parkinsoniani non depressi sono state applicate scale di valutazione della disabilità (Northwestern University Disability Scale o NUDS) e della severità dei sintomi motori “tipici” (Columbia University Rating Scale o CURS). Nei due gruppi è stata anche valutata l'eventuale presenza di decadimento intellettivo. I risultati hanno dimostrato che, mentre la severità dei sintomi “tipici” è praticamente sovrapponibile nei due gruppi, i soggetti depressi, oltre a presentare un lieve grado di decadimento intellettivo, sono significativamente più disabili (meno autonomi) dei pazienti senza depressione. Correlazione significativa è stata trovata tra gravità dei sintomi depressivi ed aumento della disabilità. Nessuna correlazione si è potuta evidenziare tra la severità dei sintomi depressivi e quella dei sintomi motori “tipici”. Nella popolazione esaminata, i sintomi depressivi sono stati riconosciuti con significativo ritardo rispetto a quelli “tipici”. Solo il 25% dei parkinsoniani depressi ha ricevuto trattamento con triciclici; il 207% circa è stato trattato con psicofarmaci dopamino-antagonisti; il 50% circa non si è visto prescrivere alcuna terapia antidepressiva. Riconoscere e trattare adeguatamente i sintomi depressivi nel parkinsoniano consente di limitare gli effetti di un importante fattore di disabilità.
    Notes: Abstract 20 depressed and 20 non depressed patients with Parkinson disease were rated for disability on the Northwestern University Disability Scale and for severity of the “typical” motor symptoms on the Columbia University Rating Scale and were assessed for mental deterioration. The severity of the “typical” symptoms was practically equivalent in the two groups but the depressed patients not only presented mild mental deterioration but were significantly more disabled (less independent) than the patients without depression. A significant correlation was found between severity of depression and degree of disability but not between severity of depression and severity of “typical” motor symptoms. Depression was diagnosed much later than the “typical” symptoms. Only 25% of the depressed parkinsonians had received tricyclic antidepressants, about 20% had been treated with dopamine-antagonist psychotropic drugs and some 50% had received no treatment at all against depression. Timely diagnosis and appropriate treatment of depression in parkinsonian patients limits the effects of a major disabling factor.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02042626
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients (1988)
    Springer
    Neurological sciences 9 (1988), S. 255-259 
    Details
    ISSN: 1590-3478
    Keywords: Parkinson disease ; levodopa ; pharmacokinetics ; on-off phenomenon
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Sommario I principali parametri farmacocinetici periferici della associazione levodopa/carbidopa sono stati studiati in 11 volontari sani ed in 16 pazienti affetti da morbo di Parkinson in differenti stadi di malattia, con e senza fluttuazioni delle performances motorie. Dopo somministrazione per via orale di una dose standard del farmaco (levodopa 250 mg., carbidopa 25 mg.), i valori della concentrazione plasmatica massima, del tempo di comparsa del picco e dell'area sotto la curva concentrazione/tempo sono risultati simili in tutti i gruppi esaminati. La farmacocinetica periferica dell'associazione levodopa/carbidopa non è risultata essere differente nei parkinsoniani che presentavano delle fluttuazioni delle performances motorie in confronto ai pazienti con stabile risposta clinica alla terapia.
    Notes: Abstract The principal peripheral pharmacokinetic parameters of the levodopa/carbidopa association were investigated in 11 healthy volunteers and in 16 patients at various stages of Parkinson disease, with and without the on-off phenomenon. After oral administration of a standard dose of drug (levodopa 250 mg + carbidopa 25 mg) the peak plasma concentrations, peak onset time and area under the curve/time proved to be similar across the groups. There was no difference in peripheral pharmacokinetics of the association between parkinsonian patients with swings in response and those without.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02334049
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients (1986)
    Springer
    Neurological sciences 7 (1986), S. 139-143 
    Details
    ISSN: 1590-3478
    Keywords: Anticholinergics ; Bornaprine ; Parkinson disease
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Sommario Sono stati esaminati 30 pazienti affetti da morbo di Parkinson idiopatico, di cui 13 maschi e 17 femmine, di età compresa tra 50 edi i 70 anni, in terapia stabilizzata con L-Dopa o con Bromocriptina o con entrambe. In tutti i soggetti, questi farmaci non consentivano un adeguato controllo della sintomatologia, con particolare riferimento al tremore. Lasciando invariata la terapia in atto, si è somministrato Bornaprine od und placebo identico, secondo una sequenza randomizzata, in doppio cieco con cross-over. I pazienti sono stati esaminati per mezzo della Webster Rating Scale a tempi predeterminati, prima, durante e dopo ciascuna fase del trattamento con farmaco o con placebo. L'analisi statistica dei risultati ha dimostrato la significativa superiorità del Bornaprine rispetto al placebo nel ridurre il tremore (p〈0.01) e, in minor misura, alcuni altri sintomi della serie parkinsoniana. Non si sono rilevati effetti collaterali di rilievo, sia dal punto di vista clinico sia da quello strumentale. L'unica eccezione è rappresentata dalla maggiore incidenza di xerostomia nel corso del trattamento con farmaco attivo rispetto a quello con placebo.
    Notes: Abstract The study covers 30 patients with idiopathic Parkinson disease, 13 men and 17 women, aged betwen 50 and 70, on stabilized L-Dopa and/or bromocriptine, which failed to ensure adequate control of the symptoms, especially tremor. To this regimen was added Bornaprine/placebo in randomized sequence. The patients were tested according to the Webster Rating Scale before, during and after each stage of the treatment. Statistical analysis of the results showed the superiority of Bornaprine over the placebo in reducing tremor (p〈0.01) and, to a lesser degree, some other parkinsonian symptoms. No noteworthy side effects were found apart from dryness of the mouth, which was more frequent with Bornaprine.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02230432
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...